Marker Therapeutics (NASDAQ:MRKR – Free Report) had its target price upped by LADENBURG THALM/SH SH from $11.00 to $19.00 in a research report report published on Monday morning, Benzinga reports. They currently have a buy rating on the stock.
Marker Therapeutics Stock Down 11.1 %
NASDAQ:MRKR opened at $4.01 on Monday. Marker Therapeutics has a 12 month low of $2.40 and a 12 month high of $6.16. The firm’s 50 day moving average is $3.15 and its 200 day moving average is $3.98.
Marker Therapeutics (NASDAQ:MRKR – Get Free Report) last issued its earnings results on Wednesday, August 14th. The company reported ($0.25) earnings per share (EPS) for the quarter. The firm had revenue of $1.17 million during the quarter. Marker Therapeutics had a negative net margin of 278.27% and a negative return on equity of 78.91%. As a group, equities research analysts anticipate that Marker Therapeutics will post -1.43 earnings per share for the current year.
Hedge Funds Weigh In On Marker Therapeutics
About Marker Therapeutics
Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens.
Featured Stories
- Five stocks we like better than Marker Therapeutics
- The Basics of Support and Resistance
- Why Meta’s Pre-Earnings Dip Could Be A Golden Entry Opportunity
- Upcoming IPO Stock Lockup Period, Explained
- Spirit Airlines Stock Nearly Doubled: Are Clear Skies Ahead?
- Roth IRA Calculator: Calculate Your Potential Returns
- Tesla Stock: Buy the Dips, Sell the Rips
Receive News & Ratings for Marker Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marker Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.